Rigel Pharmaceuticals
RIGL
131 hedge funds and large institutions have $276M invested in Rigel Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 38 increasing their positions, 35 reducing their positions, and 13 closing their positions.
42% more call options, than puts
Call options by funds: $104K | Put options by funds: $73K
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
3% more funds holding
Funds holding: 127 → 131 (+4)
9% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 35
0.2% less ownership
Funds ownership: 9% → 8.8% (-0.2%)
32% less capital invested
Capital invested by funds: $407M → $276M (-$131M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$5.12M |
| 2 |
Renaissance Technologies
New York
|
+$3.64M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.4M |
| 4 |
BlackRock
New York
|
+$1.94M |
| 5 |
Millennium Management
New York
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$6.99M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.61M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.71M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.65M |
| 5 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$2.22M |
RIGL Hedge Fund Activity: Q3 2019 in Review
131 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2019, worth a combined $276M — down 32% from $407M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new RIGL positions and 13 closed out — a net gain of 4 holders — while 38 added to existing stakes and 35 trimmed.
The largest buyer was Candriam SCA, opening a new position worth an estimated $5.12M. The largest seller was State Street, cutting an estimated $6.99M.
- 131 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2019, up from 127 in Q2 2019.
- Funds reported $276M of Rigel Pharmaceuticals stock for Q3 2019, down 32% quarter-over-quarter.
- 17 funds opened new Rigel Pharmaceuticals positions in Q3 2019 and 13 closed out, a net change of +4 holders.
- The largest Rigel Pharmaceuticals buyer in Q3 2019 was Candriam SCA, an estimated $5.12M added.
- The largest Rigel Pharmaceuticals seller in Q3 2019 was State Street, an estimated $6.99M sold.
Based on aggregated 13F filings for Q3 2019.